Carbapenem-Resistant Enterobacteriaceae: A Global Health Threat
Carbapenem-Resistant Enterobacteriaceae (CRE), now often referred to as Carbapenem-Resistant Enterobacterales, represent a critical and escalating public health crisis. They are a group of Gram-negative bacteria belonging to the *Enterobacterales* order—a large family that includes common intestinal inhabitants such as *Escherichia coli* (*E. coli*) and *Klebsiella pneumoniae*. What sets CRE apart is their resistance to carbapenems, a class of broad-spectrum antibiotics often considered the ‘last line of defense’ for treating multidrug-resistant bacterial infections. The emergence and spread of CRE fundamentally limit treatment options, leading to severe, hard-to-treat infections with significantly increased morbidity and mortality. For instance, bloodstream infections caused by CRE have been reported to have a mortality rate as high as 50%, earning them the ominous moniker of ‘nightmare bacteria’ from public health officials.
The term ‘CRE’ encompasses both organisms that exhibit resistance to at least one carbapenem antibiotic (imipenem, meropenem, doripenem, or ertapenem) and, more critically, organisms that produce a carbapenemase enzyme. These bacteria can exist in two forms within a person: colonization, where the bacteria live in the gut or on the skin without causing symptoms, or active infection, where the bacteria invade a body site and cause illness. The distinction is crucial for management, but both states allow for transmission. While CRE were fairly uncommon in the U.S. before 2000, they have become much more common since then and are now a major cause of infections in healthcare settings.
Mechanisms of Carbapenem Resistance
The primary reason for CRE’s devastating resistance profile is the acquisition of genes that code for carbapenemase enzymes. These enzymes are a type of beta-lactamase capable of hydrolyzing (breaking down) the beta-lactam ring structure essential to carbapenem antibiotics, thereby inactivating the drug. Carbapenemases are divided into different molecular classes, with the most clinically significant and prevalent types being the Class A KPC (*Klebsiella pneumoniae* Carbapenemase), the Class B metallo-beta-lactamases (MBLs) like NDM-1 (New Delhi metallo-beta-lactamase) and VIM (Verona integron-encoded metallo-beta-lactamase), and the Class D OXA-48-like enzymes. The genes for these enzymes are typically carried on mobile genetic elements called plasmids, which facilitates their rapid and efficient transfer between different bacterial species, even across the *Enterobacterales* order, a process known as horizontal gene transfer. The most common of these worldwide is KPC, which is considered endemic in several regions, including the United States.
While carbapenemase production is the most worrisome mechanism due to its high transmissibility, other non-carbapenemase mechanisms also contribute to the resistance phenotype. These include the loss or mutation of outer membrane porin proteins (e.g., OmpK35 and OmpK36 in *Klebsiella pneumoniae*). Porins act as channels for antibiotics to enter the cell; their loss prevents the carbapenem drug from reaching its target inside the bacterial cell. Changes in the porin protein hinder the diffusion of carbapenem and other antibiotics into the cell’s periplasm. A reduced influx of the antibiotic, when combined with the simultaneous overexpression of efflux pumps—systems that actively pump the antibiotic out of the bacterial cell—can also result in clinically significant carbapenem resistance. Loss of both OmpK35 and OmpK36 in *Klebsiella pneumoniae*, for example, can result in a high level of carbapenem resistance.
Epidemiology, Transmission, and High-Risk Populations
CRE infections are overwhelmingly concentrated in healthcare settings, leading to their classification as a major threat in hospitals and long-term care facilities. The spread within these environments is predominantly via person-to-person contact, often through the contaminated hands of healthcare personnel or contact with surfaces and medical equipment (e.g., bed rails, sinks, toilets) contaminated with patient bodily fluids, such as feces, wound drainage, or urine. CRE is not typically spread through the air or by casual contact like hugging. A few reports have also described spread between animals and humans, though the risk to healthy pet owners is considered low.
Healthy individuals are rarely affected; the patient population most vulnerable to CRE infection is defined by a history of extensive healthcare exposure and underlying medical fragility. Key risk factors include: prolonged or frequent stays in hospitals or long-term care facilities, especially in Intensive Care Units (ICUs); having invasive medical devices such as mechanical ventilators, urinary (bladder) catheters, or intravenous (IV) catheters, which can allow CREs to bypass natural barriers; having a weakened immune system due to conditions like cancer, organ transplantation, or diabetes; and, critically, having received long or frequent courses of broad-spectrum antibiotics, which eliminate competing susceptible bacteria and select for resistant strains. The high-risk patient often requires assistance with daily activities, which further increases the chance of coming in contact with the bacteria.
Clinical Manifestations and Diagnostic Procedures
CRE can cause a wide spectrum of infections, mirroring the types of diseases caused by non-resistant *Enterobacterales*. These include pneumonia (manifesting as shortness of breath and cough), complicated urinary tract infections (UTIs, with symptoms like pain on urination), bloodstream infections (sepsis, often presenting with fever, chills, and fatigue), wound infections (redness, swelling, and pain), and meningitis (stiff neck and reduced consciousness). The key clinical challenge is not the type of infection, but the severity and difficulty in successful antibiotic treatment, which is significantly complicated by the resistance.
Diagnosis of CRE infection relies on culturing the bacteria from a relevant body site (blood, urine, sputum, wound). Once the bacteria are isolated, laboratory confirmation requires specialized antimicrobial susceptibility testing (AST). A confirmed case involves identifying a relevant *Enterobacterales* species that is resistant to at least one of the carbapenem antibiotics. Furthermore, labs must confirm the resistance mechanism, which may involve molecular testing techniques, such as Polymerase Chain Reaction (PCR), to specifically detect the presence of a carbapenemase gene (e.g., KPC, NDM, OXA-48), or phenotypic tests like the Modified Carbapenem Inactivation Method (mCIM) or Modified Hodge Test (MHT). The lack of a set clinical case definition means CRE can represent an infection or simply colonization, making careful clinical judgment essential.
Treatment Challenges and Comprehensive Prevention Strategies
Treatment of CRE infections is complex and highly individualized because the bacteria are often resistant to multiple classes of antibiotics, not just carbapenems. Therapeutic decisions must be made on a case-by-case basis, often involving consultation with an infectious disease specialist. For uncomplicated infections like cystitis, alternative antibiotics such as trimethoprim/sulfamethoxazole, nitrofurantoin, or fosfomycin may be used if the isolate is susceptible. For severe, systemic infections, treatment typically involves combinations of older or less commonly used antibiotics to which the particular CRE strain remains susceptible, such as polymyxins (colistin), tigecycline, and aminoglycosides. The therapeutic landscape has recently improved with the introduction of novel beta-lactam/beta-lactamase inhibitor combinations, such as ceftazidime-avibactam, which are specifically designed to overcome resistance mechanisms like KPC. If no effective antibiotic can be found, supportive care becomes the primary focus for helping the patient’s body fight the infection. Colonized patients, who do not show symptoms, often do not require antibiotic treatment.
Given the limited and often toxic treatment options, prevention is the cornerstone of the public health response to CRE. Prevention strategies focus on two pillars: infection control and antimicrobial stewardship. Infection control protocols in healthcare facilities are paramount and include strict adherence to hand hygiene (washing hands with soap and water or an alcohol-based sanitizer) by staff and visitors, placing infected or colonized patients in single rooms (isolation precautions), and the consistent use of personal protective equipment (PPE) like gowns and gloves when caring for these patients. Furthermore, minimizing the use of invasive devices (e.g., catheters, ventilators) and rapidly removing them when no longer needed is a critical preventative measure. Rigorous environmental cleaning and disinfection of patient rooms and reusable medical equipment is also essential, especially surfaces that come into frequent contact with patients.
Antimicrobial stewardship, the practice of using antibiotics only when necessary and choosing the right drug at the right dose for the right duration, is equally critical. Overuse and misuse of antibiotics drive the selective pressure that leads to the emergence of resistant strains like CRE. By optimizing antibiotic prescribing, healthcare systems can reduce the pool of susceptible bacteria that might otherwise acquire resistance genes, thus slowing the rate of CRE emergence and spread. The battle against CRE is an ongoing, global effort that depends on the coordinated implementation of these robust infection prevention and antibiotic conservation measures across all levels of healthcare, from the community to the acute-care setting.